Diversity in chemotherapy-induced cachexia

Area of Science:

• Oncology
• Molecular Biology
• Gerontology

Background:

• Chemotherapy drugs like doxorubicin, folfiri, and cisplatin can induce skeletal muscle wasting and weakness, known as cachexia.
• Cancer cachexia is characterized by muscle atrophy, protein breakdown, and mitochondrial dysfunction, with variations in molecular pathways among different agents.
• Muscle wasting can occur early during cancer treatment and persist, impacting patients with various malignancies, including gastrointestinal, head and neck, and non-small cell lung cancers.

Purpose of the Study:

• To examine the diversity of chemotherapy-induced cachexia.
• To explore differences in cachexia development based on specific chemotherapy regimens, cancer types, patient age, and sex.

Main Methods:

• Review of preclinical and clinical studies on chemotherapy-induced cachexia.
• Analysis of commonalities and distinguishing features of cachexia induced by doxorubicin, folfiri, and cisplatin.
• Examination of age- and sex-related differences in cachexia onset and progression.

Main Results:

• Chemotherapy regimens, cancer types, age, and sex are all factors influencing the development and presentation of cancer cachexia.
• Preclinical studies often use younger models, while clinical studies focus on older patients, highlighting a gap in understanding age-related effects.
• Sex differences in chemotherapy-induced cachexia are observed, suggesting potential for sex-specific treatment strategies.

Conclusions:

• Chemotherapy-induced cachexia is a complex condition with varied manifestations.
• Further research is needed to understand the specific impact of different chemotherapies, cancers, age, and sex on cachexia.
• Tailoring cachexia treatments based on patient-specific factors like age and sex may improve outcomes.